Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 13, 2018

SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27 th at 1:30 p.m. EST . The presentation will be webcast live on the Events and

Additional Formats
Sep 07, 2018

- Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community - SOUTH PLAINFIELD, N.J. , Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize

Additional Formats
Aug 24, 2018

SOUTH PLAINFIELD, N.J. , Aug. 24, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 22 , 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.

Additional Formats
Aug 23, 2018

SOUTH PLAINFIELD, N.J. , Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc. , a private biotechnology company focused on the advancement of innovative gene therapy programs for rare

Additional Formats
Aug 10, 2018

SOUTH PLAINFIELD, N.J. , Aug. 10, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 6 , 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.

Additional Formats
Aug 07, 2018

Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children as young as 2 years of age Compelling data from FIREFISH study SOUTH PLAINFIELD, N.J. , Aug.

Additional Formats
Aug 02, 2018

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea - SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

Additional Formats
Jul 26, 2018

SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7,

Additional Formats
Jul 24, 2018

- Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve - SOUTH PLAINFIELD, N.J. , July 24, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and

Additional Formats
Jul 19, 2018

- Expands and diversifies current pipeline with four gene therapy programs - - BLA submission in AADC deficiency expected in 2019 - SOUTH PLAINFIELD, N.J. , July 19, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Agilis

Additional Formats